NCT07069309View on ClinicalTrials.gov

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

January 6, 2026

Study Completion Date

January 6, 2026

Conditions
COVID-19SARS-COV-2 Infection
Interventions
BIOLOGICAL

BNT162b2 (Omi LP.8.1)

BNT162b2 monovalent (Omicron LP.8.1)

Trial Locations (6)

28401

RECRUITING

Accellacare - Wilmington, Wilmington

33012

RECRUITING

Indago Research & Health Center, Inc, Hialeah

65802

RECRUITING

Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield

65807

RECRUITING

Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center, Springfield

84109

RECRUITING

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

94598

RECRUITING

Diablo Clinical Research, Inc., Walnut Creek

Sponsors

Lead Sponsor

BioNTech SE

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT07069309 - A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19 | Biotech Hunter | Biotech Hunter